⌘K
t
On 26 May 2023, Nick Rodgers, Chairman of Destiny Pharma plc, purchased 20,000 ordinary shares of 1 pence each in the Company. These shares were acquired at a price of 30.19 pence per share. Following this transaction, Mr. Rodgers' beneficial interest totals 238,901 Ordinary Shares, representing 0.25 per cent. of the total issued share capital.
| Date | 26 May 2023 |
| Time | 15:27:34 |
| Category | Director/PDMR dealings |
| ID | 8614A |
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Director/PDMR Shareholding
Brighton, United Kingdom - 26 May 2023 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that it was notified on 26 May 2023 that on that same day, Nick Rodgers, Chairman of the Company, purchased 20,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 30.19 pence.
Following the purchase, Mr. Rodgers' beneficial interest in the Company is 238,901 Ordinary Shares, representing 0.25 per cent. of the total issued share capital.
For further information, please contact:
Destiny Pharma plc
Dr Debra Barker, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0)20 7220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
Optimum Strategic Communications
Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper
+44 (0) 203 922 0891
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has completed a positive Phase 2 clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.
For further information on the Company, please visit https://www.destinypharma.com
Further information is disclosed below pursuant to Article 19(3) of the Market Abuse Regulation.
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Nick Rodgers |
||||
|
2. |
Reason for the Notification |
|||||
|
a) |
Position/status |
Chairman |
||||
|
b) |
Initial notification/Amendment |
Initial Notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Destiny Pharma plc |
||||
|
b) |
LEI |
213800O9WH9Z38EHAC95 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the Financial instrument, type of instrument |
Ordinary shares of 1 pence each in Destiny Pharma Plc |
||||
|
Identification code |
GB00BDHSP575 |
|||||
|
b) |
Nature of the transaction |
Purchase of Ordinary Shares |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information: · Aggregated volume · Price |
See 4c) above |
||||
|
e) |
Date of the transaction |
26 May 2023 |
||||
|
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
||||